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UbiquitinationPeroxisomal biogenesis disorders (PBDs) represent a spectrum of autosomal recessive metabolic disorders
that are collectively characterized by abnormal peroxisome assembly and impaired peroxisomal function.
The importance of this ubiquitous organelle for human health is highlighted by the fact that PBDs are mul-
tisystemic disorders that often cause death in early infancy. Peroxisomes contribute to central metabolic
pathways. Most enzymes in the peroxisomal matrix are linked to lipid metabolism and detoxiﬁcation of
reactive oxygen species. Proper assembly of peroxisomes and thus also import of their enzymes relies on
speciﬁc peroxisomal biogenesis factors, so called peroxins with PEX being the gene acronym. To date, 13
PEX genes are known to cause PBDs when mutated. Studies of the cellular and molecular defects in cells
derived from PBD patients have signiﬁcantly contributed to the understanding of the functional role of the
corresponding peroxins in peroxisome assembly. In this review, we discuss recent data derived from both
human cell culture as well as model organisms like yeasts and present an overview on the molecular mech-
anism underlying peroxisomal biogenesis disorders with emphasis on disorders caused by defects in the per-
oxisomal matrix protein import machinery. This article is part of a Special Issue entitled: Metabolic Functions
and Biogenesis of Peroxisomes in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Peroxisomes — general introductionPeroxisomes are single membrane bound, dynamic organelles of
eukaryotic cells. They were ﬁrst identiﬁed in the electron microscopy
images of mouse kidney cells [1]. They are mostly spherical, 0.1 to
1 μm in diameter and surrounded by a single lipid bilayer membrane
[2]. They do not contain DNA or a protein translation machinery and
hence import nuclear coded proteins synthesized in the cytosol post-
translationally [3]. The number, size and function of peroxisomes de-
pend on the cell type or organism and the environmental conditions.
This is also reﬂected by their unique variability in enzyme content
and thus metabolic functions, whichmarks them as “multi-purpose or-
ganelles” that adjust their metabolic capabilities according to the cellu-
lar needs [4]. Until now 50 different enzymes have been identiﬁed in
the peroxisomalmatrix, which are linked to different biochemical path-
ways. However, the central function of these organelles in all instances
is β-oxidation of fatty acids and hydrogen peroxide detoxiﬁcation.lic Functions and Biogenesis of
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l rights reserved.Unlike in yeast and plants, β-oxidation of fatty acids occurs in both per-
oxisomes and mitochondria of mammalian cells. Very long chain fatty
acids, long chain dicarboxylic acids, some unsaturated fatty acids,
pristanoic acids, di and tri-hydroxycholestanoic acids are metabolized
in peroxisomes. In humans, peroxisomes are also involved in synthesis
of cholesterol, bile acids and ether lipids such as plasmalogens, which ac-
count for themajor portion of the ethanolamine glycerophospholipids in
the adult human brain, notably 80–90% of these lipids in the white mat-
ter of the brain [5–10]. Apart from the above mentioned functions, re-
cently a role for peroxisomes in the antiviral innate immunity has been
described. In mouse embryonic ﬁbroblasts and human hepatocytes, the
antiviral signaling protein MAVS (mitochondrial antiviral-signaling pro-
tein) has been localized to both peroxisomes and mitochondria. The
data demonstrate that peroxisomes provide a signiﬁcant site of antiviral
signal transduction and that they promote a rapid response to viral infec-
tion [11].
After their initial description in 1954 [1], peroxisomes were ﬁrst
associated with human disease in 1973, when it was discovered that
kidney and liver tissue from Zellweger syndrome patients were devoid
of peroxisomes [12]. In 1984, a speciﬁc biomarker was identiﬁed [13]
that could be used for the screening of patients and the ﬁrst gene defect
associated with a peroxisomal biogenesis defect was identiﬁed in 1992
[14].
The ﬁnding that peroxisomes constitute the sole site for breakdown
of fatty acids in fungi and the synthesis of plasmalogens in mammalian
cells, has been used for the screening of yeast [15] and Chinese hamster
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mutants were instrumental for the identiﬁcation of the corresponding
genes by functional complementation which led to the discovery of
the ﬁrst proteins essential for peroxisome formation [17,18]. Most of
the currently known peroxisome biogenesis factors, collectively called
peroxins (PEX), were identiﬁed by these genetic approaches, some
later on by proteomic approaches [19] or as in the case of the recently
discovered PEX34, by their interaction with known peroxins [20].
Apart from the study of their metabolic functions another widely
studied research area is peroxisome biogenesis. Essential aspects of
peroxisome biogenesis concern the cellular origin of the organelle
and the matrix and membrane protein import, which are completely
independent processes. A role for the endoplasmic reticulum (ER) in
the origin of peroxisomal membrane was hypothesized initially
based on the close proximity of ER and peroxisomes in electron mi-
crographs [21]. However the post-translational import of peroxisomal
proteins developed the idea of peroxisomes as an autonomous organ-
elle which multiply by growth and division [22]. This concept of per-
oxisomes being autonomous organelles was challenged with the
discovery that peroxisomes can be formed from the endoplasmic re-
ticulum upon the reintroduction of Pex3 in peroxisome-deﬁcient
cells. [23–25]. While, the possibility of de novo formation of peroxi-
somes is now well accepted, the signiﬁcance of this contribution to
the peroxisome content is still under debate. While one view is that
all peroxisomal membrane proteins trafﬁc via the ER [26], other
work demonstrates that under wild type conditions peroxisomes
are generally formed by growth and division and only under circum-
stances when there are no peroxisomes in a cell, they can be formed
from the ER after reintroduction of the corresponding gene [27]. Also
in higher eukaryotes, it is shown that peroxisomal membrane pro-
teins are directly targeted to peroxisomes [28]. Several recent data,
however, point towards a more semi-autonomous nature of peroxi-
somes, where certain peroxisomal membrane proteins might trafﬁc
to peroxisomes via the ER [29–31].
In contrast to peroxisomal membrane protein targeting, the basic
principles of matrix protein import are widely accepted. The ability
to import folded, co-factor bound and oligomeric proteins distinguishes
peroxisomes from other organelles like mitochondria [32–34].
The importance of peroxisomes for human health is highlighted
by severe inborn peroxisomal diseases. These can be caused by defects
in peroxisome biogenesis or can be due to peroxisomal single enzyme
deﬁciencies. Peroxisome biogenesis disorders are caused by defects
in PEX genes. At present, 33 different PEX genes are known and 13
orthologous human PEX genes have been described (Table 1).
In this review, we focus on the import of peroxisomal matrix pro-
teins and the importance of this process for humans. We highlight the
increased understanding of the molecular mechanism of this trans-
port process and explain the manifestation of the severe peroxisomal
biogenesis disorders (PBD), which occur when this import process is
defective. Recent developments of various animal models and thera-
peutic strategies for mild PBDs associated with a defective matrix im-
port will also be discussed here.
2. Matrix protein importA remarkable feature of peroxisomes is the import of fully folded
even oligomeric and co-factor bound proteins [35]. This import pro-
cess can be divided into ﬁve steps as (i) cargo recognition, (ii) receptor
docking, (iii) cargo translocation, (iv) cargo release and (v) receptor
release and recycling (Fig. 1).
2.1. Cargo recognition by the import receptors in the cytosol
Proteins that are to be imported into the peroxisomal matrix typ-
ically contain one of the two peroxisome-targeting signals (PTS1 andPTS2). Notable exceptions are C. elegans and diatoms, which have lost
the genes for targeting PTS2 proteins during evolution and import all
matrix proteins via PTS1 signals [36,37].
PTS1 was initially discovered as the carboxyterminal tripeptide
SKL in the ﬁreﬂy luciferase protein [38]. Sequence comparisons be-
tween species led to a consensus sequence (S/A/C)-(K/R/H)-(L/M) [39].
In recent years, it became clear that additional amino acid residueswith-
in the cargo protein are of relevance for the interaction with the PTS1-
receptor, which led to a reﬁnement of the deﬁnition of the PTS1 [40].
The PTS1 as a targeting signal is used by majority of the peroxisomal
proteins. Mammalian catalase and alanine-glyoxylate aminotransferase
are examples of two proteins that need interactions in addition to the
binding of the PTS1 for proper targeting to the peroxisomes. A KANL
sequence at the C-terminus is required for the targeting of mammalian
catalase [41] whereas two signals are required for the targeting of
alanine-glyoxylate aminotransferase, a C-terminal KKKL and an internal
eight amino acid sequence [42]. The PTS2 is located near the N-terminus
of the proteins and conforms to themotif R-(L/V/I/Q)-xx-(L/V/I/H)-(L/S/
G/A)-x-(H/Q)-(L/A) [43]. Very few proteins are targeted to the peroxi-
somes by PTS2 in mammals. However, in plants approximately one
third of the peroxisomal proteins are targeted via the PTS2 pathway
[44]. In Saccharomyces cerevisiae, thiolase (Fox3) and glycerol phosphate
dehydrogenase (Gpd1) are the only proteins known to use the PTS2
[45,46].
Proteins that harbor a peroxisomal targeting signal are recognized
by their respective receptors in the cytosol — which is Pex5 for the
PTS1 [47] and Pex7 for the PTS2 import [48]. The C-terminal domain
of Pex5 binds to the PTS1 sequence of the cargo and is characterized
by seven tetratricopeptide repeats. Pex7 is aWD40 proteinwhich recog-
nizes the PTS2 signal. A major difference between Pex5 and Pex7 is that
Pex5 functions independently whereas Pex7 requires co-receptors such
as Pex18 and Pex21 in S. cerevisiae or Pex20 in Yarrowia lipolytica, Pichia
pastoris, Hansenula polymorpha and Neurospora [49–51]. Humans and
plants lack these co-receptors but express a longer splice variant of
Pex5 which contains a Pex7 binding site [52–54]. Two isoforms of
Pex5 are present inmammalian cells, namely a short (Pex5S) and a lon-
ger species (Pex5L). Both of these isoforms function as PTS1 receptors
whereas only Pex5L is also required for PTS2 import due to its additional
Pex7-binding domain [53]. Thus, while PTS1 and PTS2 import pathways
function independently in yeasts and fungi, they converge in higher
eukaryotes such as mammals and plants already at the level of cargo
recognition.
While most peroxisomal proteins use either the PTS1 or PTS2 sig-
nal for targeting, there are some proteins which do not contain such
a signal [55]. Interestingly, the import of these non-PTS proteins still
depends on the presence of Pex5, mostly via an interaction to the
N‐terminal portion of Pex5. Some examples include acyl-CoA oxidase
in S. cerevisiae and Y. lipolytica, alcohol oxidase inH. polymorpha [56,57].
Moreover, some proteins that lack a PTS might hijack the PTS-pathway
by piggy-backing onto proteins that do contain a PTS. Enoyl-CoA
isomerases Eci1 and Dci1 in S. cerevisiae and the ﬁve acyl-CoA oxi-
dase isoforms in Y. lipolytica are examples for this mechanism [58,59].
Also in mammals, the copper–zinc superoxide dismutase 1 (SOD1), a
non-PTS protein, is targeted to peroxisomes with the aid of its inter-
acting partner, the copper chaperone of SOD1 [60].
2.2. Docking of the receptor/cargo complex at the membrane
Subsequent to the formation of the receptor–cargo complex in the
cytosol, the receptor ferries the cargo protein to the peroxisomal
membrane. The membrane-bound peroxins Pex13 and Pex14 are re-
quired for the initial binding step. Lack of one of these docking com-
plex peroxins signiﬁcantly affects the import of both PTS1 and PTS2
targeted proteins into the peroxisome [61–66]. Pex13 is an integral
membrane protein and binds to Pex14 by its SH3 domain which con-
tains a proline rich SH3 ligand motif. However, a second binding site
Table 1
Peroxisomal biogenesis factors and associated biogenesis disorders. The table lists the known human and S. cerevisiae proteins required for peroxisomal biogenesis. Abbreviations
used are IRD (infantile Refsum disease), NALD (neonatal adrenoleukodystrophy), RCDP1 (Rhizomelic Chondrodysplasia Punctata type 1) and ZS (Zellweger syndrome). The asterisk
* points out that the protein is absent in S. cerevisiae and other yeast species with an exception of Y. lipolytica. The✓marks the corresponding matrix protein import defect. The (✓)
indicates a stress-related matrix protein import defect. For detailed information we refer to the text and for cross-references to [20,35,102,103,113,116–118,127,129,133].
Role H. sapiens S. cerevisiae Human disease Gene deletion phenotype
in S. cerevisiae —
mislocalization of matrix
proteins
PTS1 PTS2
Matrix protein import
PTS1 receptor Pex5 Pex5 ZS, NALD ✓
PTS2 receptor Pex7 Pex7 RCDP1, Adult Refsum disease ✓
PTS2 co-receptor Pex5L Pex18 ✓
Pex21 ✓
Docking complex Pex13 Pex13 ZS, NALD ✓ ✓
Pex14 Pex14 ZS ✓ ✓
Pex17 ✓ ✓
Importomer assembly Pex8 ✓ ✓
RING ﬁnger ligase complex Pex2 Pex2 ZS, IRD ✓ ✓
Pex10 Pex10 ZS, NALD ✓ ✓
Pex12 Pex12 ZS, NALD, IRD ✓ ✓
Receptor ubiquitin conjugation UbcH5a/b/c Pex4 Unknown ✓ ✓
(E2D1/2/3)
Pex22 ✓ ✓
Receptor deubiquitination Ubp15 (✓) Unknown
USP9X Unknown
AAA export complex Pex1 Pex1 ZS, NALD, IRD ✓ ✓
Pex6 Pex6 ZS, NALD, IRD ✓ ✓
Pex26 Pex15 ZS, NALD, IRD ✓ ✓
AWP1 Unknown
Membrane biogenesis and regulatory peroxins Gene deletion phenotype
in S. cerevisiae
Membrane biogenesis Pex3 Pex3 ZS Absence of peroxisomes
Pex19 Pex19 ZS Absence of peroxisomes
Pex16 (Pex16)* ZS
Peroxisome proliferation Pex11α,β,γ Pex11,25,27 Unknown Reduced number of
peroxisomes
Regulation of size, number and distribution Pex28–32, Pex34 Altered peroxisome
number and/or
morphology
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the interactions of Pex13 with Pex14 are mediated by several
direct or indirect interactions [67]. The N-terminus of Pex13 binds
to Pex7 and the SH3 domain interacts with the WXXXF/Y motif of
the PTS1 receptor in yeast [63,65,66,68]. However, the Chinese hamster
Pex5 does not interact with the SH3 domain of Pex13 but interacts
with its N-terminus which also contains the Pex7 binding region
[69].
Pex14 is an integral peroxisomal membrane protein in most spe-
cies but in some species it is also described to be peripherally associ-
ated with the peroxisomal membrane [61,70–72]. Several studies
suggest that Pex14 is the initial docking protein. NMR and crystal
structures have revealed a structural basis for the Pex14 and Pex5 in-
teractions [73,74]. The interaction between Pex14 and Pex5 is shown to
be mediated by the Pex5 WXXXF/Y motifs. The N-terminus of Pex14
comprises two hydrophobic cavities which recognize the WXXXF/Y
motif of Pex5. These hydrophobic cavities are separated by two aromat-
ic residues and are ﬂanked by several basic amino acids leading to a
positively charged protein surface. The Pex5 peptide adopts an amphi-
pathic α-helical conformation in the Pex5–Pex14 complex structure
and binds diagonally across helices α1 and α2 in Pex14 [73].
Yeast Pex17 is a peripheralmembrane protein of unknown function,
which associates to peroxisomes via Pex14 [75,76]. A homolog of Pex17
in higher eukaryotes has not yet been identiﬁed. In ﬁlamentous fungi,
a chimeric protein that consists of Pex14-like N-terminal domain and
a Pex17-like C-terminal domain has been described [77,78]. In yeast,deﬁciency of Pex17 affects import of PTS1 aswell as PTS2 proteins, how-
ever, the functional role of the protein remains enigmatic [75,76].2.3. Cargo translocation
The import of folded and in some cases even cofactor bound or
oligomerized proteins into the matrix distinguishes peroxisomes sig-
niﬁcantly from mitochondria and chloroplasts. However, it remained a
matter of speculation for a long time how the cargo proteins traverse
the membrane without affecting the permeability barrier. One hypoth-
esis was that the import receptors themselves might temporally be-
come part of the dynamic import pore [79]. This was mainly based on
the observations that the PTS1-receptor Pex5 can bind lipids and
changes its topology at the peroxisomal membrane. At the membrane,
it is partially carbonate resistant, adapts a partial protease-protected
state and thus behaves like an integral membrane protein [80–82]. In
line with this view, Pex5 together with Pex14 turned out to represent
the minimal unit for the import of the intraperoxisomal protein Pex8
in P. pastoris [83]. Furthermore, by the use of the planar lipid bilayer
technique, it has been shown that the import receptor Pex5 and its
docking protein Pex14 in the presence of a cargo protein form a pore
with features expected for a protein-conducting channel [84]. More-
over, the dynamic behavior and physical properties of this channel
with a diameter of up to 9 nm appear to fulﬁll the criteria for the pas-
sage of folded proteins. However, the exact composition of this pore
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location is still to be disclosed.2.4. Cargo release into the matrix
The release of the cargo into the peroxisomal lumen after transloca-
tion is still not well characterized. A role for the less conserved yeast
Pex8 in this process has been suggested. Pex8 is an intra-peroxisomal
peripheral membrane protein, which contains both PTS1 and PTS2 sig-
nals for its targeting to peroxisomes [85,86]. There is some evidence for
the role of S. cerevisiae Pex8 in the dissociation of the PTS1-receptor
cargo complex [87]. Another function assigned to S. cerevisiae Pex8
is that it is required to physically connect the docking complex to
the RING ﬁnger complex of the export machinery (see below) [88].
However, this structural function seems to be taken over in P. pastoris
by Pex3 [89]. As Pex8-like proteins are not yet identiﬁed in humans,
the general mechanism of cargo release remains elusive.
A role for Pex14 in the release of catalase from the translocation
machinery into the matrix has been suggested recently [90]. The au-
thors suggest that the release of the cargo is facilitated by the interac-
tion of Pex5 with the N-terminal domain of Pex14 molecules at the
translocation machinery.
After the release into the matrix, a subset of proteins is processed
in peroxisomes of mammals and plants [91,92]. In mammalian cells,
the intraperoxisomal protease Tysnd1 is responsible both for the re-
moval of the leader peptide from PTS2 proteins and for the speciﬁc
processing of PTS1 proteins. Tysnd1 turned out to be a key regulator
of the peroxisomal β-oxidation pathway. The proteolytic activity of
oligomeric Tysnd1 is controlled by self-cleavage and the degradation
products are removed by the peroxisomal Lon protease [91–93].Fig. 1. Composite model of peroxisomal matrix protein import. Proteins harboring a peroxis
in the cytosol and proteins with the PTS2 sequence are recognized by Pex7 and the cofacto
receptor–cargo complex is directed to the peroxisomal membrane and associates with the
of the cargo-loaded Pex5 with the docking complex results in the formation of a transient p
of the pore yet have to be identiﬁed. The cargo is translocated into the peroxisomal lumen
released into the peroxisomal lumen, a process which possibly involves Pex8 in yeast. The R
together with ubiquitin-conjugating enzymes Pex4 and its membrane anchor Pex22 in yeast
ubiquitination. This modiﬁcation serves as a signal for the ATP-dependent dislocation of Pe
Pex6. Pex1 and Pex6 are anchored to the peroxisomal membrane via Pex15 in yeast and P
redundant proteins Ubc5 and Ubc1 polyubiquitinate Pex5 which is then degraded by the 26
the modiﬁcation by monoubiquitination primes Pex5 for new round of import. The AAA p
while human Pex6 interacts with AWP1, an adaptor protein for ubiquitinated Pex5 in human
components present in yeast and humans are depicted in different font colors. Black — comp
components speciﬁc to yeast.2.5. Receptor ubiquitination and recycling
Subsequent to cargo liberation, the PTS-receptors return to the cy-
tosol for further rounds of import. Early studies discovered that the
peroxisomal matrix protein import is an energy-dependent process
requiring the hydrolysis of ATP [94]. The idea of import receptors
shuttling between the peroxisomal membrane and the cytosol was
ﬁrst described byMarzioch et al. (1994) [95], based on the predominant
cytosolic localization of the PTS2-receptor. Investigations in perme-
abilized cell systems of human ﬁbroblasts provided the ﬁrst evidence
for cycling of the PTS1 receptor as the protein accumulated reversibly
at the peroxisomalmembrane under conditionswhen protein transport
was blocked [96]. Furthermore, in vitro studies revealed that the binding
and translocation of Pex5 does not require ATPwhile the export of Pex5
back to the cytosol is the ATP-dependent step [97]. The corresponding
ATPase was identiﬁed as the peroxisomal AAA (ATPases associated
with diverse cellular activities)-complex, consisting of Pex1 and Pex6,
both in human [98] and yeast cells [99]. The function of Pex1 and Pex6
is not redundant [86,87] and depends on the presence of their mem-
brane anchor, Pex26 in mammalian cells and its ortholog Pex15 in
yeast [100,101]. The binding and consumption of ATP by the AAA pro-
teins are believed to induce conformational changes that generate
the driving force to pull the receptor out of the membrane [102,103].
The exact mechanism of substrate recognition and extraction from
the membrane is not known. However, it has become increasingly
clear that ubiquitination of the PTS-receptor plays amajor role in the re-
ceptor release. Ubiquitination is a highly conserved post-translational
modiﬁcation that is catalyzed by a three-step enzyme cascade
(E1, E2, E3) and results in the covalent attachment of the 76 amino
acid comprising ubiquitin to a substrate [104]. Pex5 exhibits two differ-
ent modes of ubiquitination, mono and polyubiquitination. Foromal targeting signal type 1 (PTS1) are recognized by the soluble import receptor Pex5
rs Pex18 and Pex21 in S. cerevisiae, Pex5L in plants and mammals. After this step, the
docking complex consisting of Pex14 and Pex13 as well as Pex17 in yeast. Assembly
ore, which mainly consists of Pex5 and Pex14. The exact architecture and components
in an unknown manner. The receptor–cargo complex then dissociates and the cargo is
ING-complex comprises Pex2, Pex10 and Pex12 which all are ubiquitin ligases, which
or the Pex4-like isoforms UbcH5 a, b, c in mammals are responsible for receptor mono-
x5 from the peroxisomal membrane back to the cytosol by the AAA peroxins Pex1 and
ex26 in mammals. In yeast the ubiquitin-conjugating enzyme Ubc4 together with the
S proteasome. Thus, while polyubiquitination directs Pex5 to a quality control pathway,
eroxin Pex6 in yeast interacts with Ubp15, a deubiquitinating enzyme acting on Pex5,
s. In mammals, Pex5 is deubiquitinated by USP9X in the cytosol. The import machinery
onents present in both yeast and human, red— components speciﬁc to humans, blue —
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thioester bond to a conserved cysteine residue of the receptor whereas
attachment of ubiquitin to conserved lysine residues and subsequent
ubiquitination of the attached ubiquitin results in polyubiquitination.
The polyubiquitination cascade acting on Pex5 has been unraveled
in S. cerevisiae. Here, the ubiquitin-conjugating enzyme (E2) Ubc4
and the partially redundant Ubc5 and Ubc1 are required for poly-
ubiquitination of Pex5 [105,106]. Both Pex2 and Pex10 have been
suggested to function as the corresponding ubiquitin-ligases (E3)
[107,108]. Polyubiquitinated Pex5 is degraded in the 26S proteasome
and thus is considered as a quality control system for aberrant PTS1-
receptor molecules [105,106].
Themonoubiquitination of Pex5 on a conserved cysteine is a prereq-
uisite for the export of the PTS1-receptor back to the cytosol [109–111]
and thus is essential for peroxisomal biogenesis. The E2 protein Pex4
together with its membrane anchor Pex22 is required for this modiﬁca-
tion in yeast [111,112] while in mammals the Pex4-like isoforms
UbcH5a, UbcH5b; and UbcH5c (also known as UBE2D1, UBE2D2,
UBE2D3) catalyze the cysteine-dependent ubiquitination [113]. Fur-
thermore, the E3 ligase Pex12 is also required for this process [107].
The ubiquitin moiety needs to be removed from the mon-
oubiquitinated Pex5 before it can enter a new round of import. This
cleavage of ubiquitin from the substrate is generally carried out by
ubiquitin hydrolases also called deubiquitinating enzymes [114]. Re-
cent in vitro data obtained from rat suggests that the monoubiquitin
moiety of Pex5 can be cleaved in two ways, a non enzymatic release
of the thioester bond between Pex5 and mono-Ub by a nucleophilic
attack of glutathione or, as the major pathway, enzyme catalyzed by
ubiquitin hydrolases [115]. Ubp15 was identiﬁed as such an ubiquitin
hydrolase in S. cerevisiae. The protein is a novel interaction partner of
Pex6 and functions as a deubiquitinating enzyme acting on Pex5 [116].
Recently, its putativemammalian ortholog, the ubiquitin-speciﬁc prote-
ase 9X (USP9X) has been identiﬁed as a deubiquitinase acting on the
ubiquitin-Pex5 thioester conjugate [117].
While it seems clear that the purpose of monoubiquitination is to
prime Pex5 for export mediated by the AAA peroxins as part of the
recycling pathway, the mechanistic role of the modiﬁcation remains
to be investigated. In this respect, the recent discovery of a novel
adaptor protein of human Pex6, AWP1 could provide a mechanistic
link [118]. AWP1, which has been described before to function as a
ubiquitin-binding NF-kappaB modulator, is able to interact with both
Pex6 and monoubiquitinated Pex5 and thus might function as a selec-
tive linker, which enables the AAA proteins to transfer their suggested
pulling force to the receptor molecule intended for export.
Not only the PTS1-receptor Pex5, but also components of the PTS2
pathway are ubiquitinated. The co-receptors Pex18 in S. cerevisiae
[119,120] and Pex20 in P. pastoris [121,122] are ubiquitinated at the
peroxisome membrane and this modiﬁcation is crucial for PTS2-co-
receptor recycling.
2.6. Possible link between receptor export and cargo release: the export
driven import model
The components of the peroxisomal import receptor ubiquitination
and export machinery are evolutionarily related to the proteins of
the Endoplasmic Reticulum Associated Degradation (ERAD) machinery
[123–125]. ERAD represents a mechanism by which misfolded and
polyubiquitinated proteins are extracted from the ER for their subse-
quent proteasomal degradation [126]. The structural and functional
similarities of ERAD and the peroxisomal receptor cycle might provide
a clue to how the energy-requirement of matrix protein import might
be connected to the translocation of the cargo through the import pore.
The similarity between both machineries is that they use ubiquitination
to mark proteins for ATP-dependent release from the membrane. How-
ever, the target for ubiquitination is different in both cases — in ERAD
the cargo is ubiquitinated, released and directed for proteasomaldegradation whereas in the case of the peroxisomal import the peroxi-
somal receptors aremodiﬁed. Thus, the receptors in peroxisomal protein
import behave like the cargos in ERAD. These considerations led to the
export-driven import model proposing that the ERAD-like removal of
the peroxisomal import receptor is linked to protein import [124].
In support of this model, the presence of a functional receptor–export
complex is a pre-requisite for the import of matrix proteins into peroxi-
somes. This mode of protein translocation is dependent on ATP and the
AAA-dependent energy driven extraction of the receptor from the im-
port pore is supposed to be coupled to the movement and translocation
of the cargo across the membrane [124]. Recently, work on the
ubiquitination of the PTS2-co-receptor Pex18 in S. cerevisiae provided
direct evidence for this model as the cysteine-dependent mono-
ubiquitination of Pex18 which is required for receptor export was
found to be a prerequisite for translocation of cargo-loaded Pex7 across
the peroxisomal membrane [119].
3. Peroxisomal matrix protein import defects and human disorders
A wide spectrum of disorders is associated with defects in peroxi-
some biogenesis affecting speciﬁc steps like matrix protein import,
peroxisome membrane biogenesis or organelle division [127,128].
Peroxisome biogenesis disorders (PBD) can be generally divided into
two subsections namely Zellweger syndrome spectrum (ZSS) and clin-
ically distinct rhizomelic chondrodysplasia punctata type 1 (RCDP1).
The ZSS is a genetically heterogeneous group of disorders with over-
lapping clinical phenotypes, which includes the most severe Zellweger
syndrome (ZS), less severe neonatal adrenoleukodystrophy (NALD)
and relatively milder infantile Refsum disease (IRD). Neurological ab-
normalities and developmental defects are common in PBD patients
which appear early after birth. Abnormalities in fatty acid metabolism
lead to changes in the levels of various metabolites like very long
chain fatty acids (VLCFA) or plasmalogens [129]. Several diseases are
also attributed to single peroxisomal enzyme deﬁciencies [130] or de-
fects in fatty acid transport across the peroxisomal membrane [131].
This review focuses mainly on disorders caused by matrix protein im-
port defects as well as on recent developments in animal models to
study such disorders and novel therapeutic strategies.
Experimental studies on the ﬁbroblasts isolated from patients
suffering from PBDs led to the observation of distinct types of perox-
isomal protein import defects at a subcellular level. Various strategies
were employed to dissect the degree of these import defects. Slawecki
et al. [132] conducted immunoﬂuorescence microscopy studies using
antibodies against the PTS1 (−SKL) or the PTS2 protein thiolase while
more recently Ebberink et al. [133] used ﬂuorescent marker proteins
GFP–PTS1 or PTS2–GFP to elucidate the import defects in over 600 PBD
patient cell lines. Three types of matrix protein import defects were
observed: (i) defects in PTS1 protein import, (ii) defects in PTS2 protein
import and (iii) defects in PTS1 as well as PTS2 protein import (Table 1).
3.1. Defects in PTS1 protein import
As described in Section 2.1, Pex5 is the receptor for peroxisomal
targeting of PTS1-containing proteins. Human Pex5 was identiﬁed
by Dodt et al. based on sequence homology with P. pastoris Pex5
and it was shown that mutations in Pex5 lead to PBDs (118).
Unlike human cells, yeast cells that completely lack Pex5 still
exhibit normal PTS2 import. Yeast Pex7 binds to the co-receptors
Pex18 and Pex21 (S. cerevisiae) or Pex20 (Y. lipolytica, H. polymorpha)
and the peroxisomal targeting of PTS2-proteins in yeast occurs inde-
pendent of the Pex5 import pathway [52]. In humans, PTS2 protein
import is dependent on Pex5 since Pex7 requires the longer splice
isoform as a co-receptor [52]. Ebberink et al. [133] performed an anal-
ysis of mutations in patient cell lines and found 11 different muta-
tions in Pex5, out of which 4 mutations lead to a speciﬁc defect in the
import of PTS1 containing proteins. These four mutations lie in regions
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or regions required for interaction with Pex13 or Pex14. Consequently,
PTS2 import is normal in these cell lines. In contrast, the remaining
seven Pex5 mutations lead to the loss of both PTS1 and PTS2 protein
import, resulting in the severe clinical Zellweger phenotype (see
Section 3.3) [52,132,133].
Only PTS1 protein import defects are associated with the disorder
NALD. Elevated levels of VLCFA and pipecolic acid are accompanied by
a deﬁciency in plasmalogens. Clinical symptoms include neurological
abnormalities like de-myelination, hypotonia, seizures, sensorineural
hearing loss and psychomotor retardation [134].
3.2. Defects in PTS2 protein import
Although the PTS2 signal is less commonly utilized for peroxisomal
targeting in humans [44], crucial metabolic enzymes like 3-ketoacyl
Co-A thiolase (VLCFA metabolism), alkylglycerone phosphate synthase
(AGPS) (plasmalogen synthesis) and phytanic acid co-A hydrolase
(PHYH) (phytanic acid catabolism) are targeted by this pathway in
humans. Speciﬁc defects in the PTS2 import, potentially caused by
mutations in Pex7 or the Pex7-binding region in Pex5L, lead to the
mislocalization of PTS2 proteins while PTS1 import is not affected.
Metabolic abnormalities caused by speciﬁc PTS2 import defects are
associatedwith RCDP1 disorderwhich differs genetically aswell as clin-
ically from PBD, ZSS [135,136]. RCDP1 patients have plasmalogen deﬁ-
ciency and elevated levels of phytanic acid due to the mislocalization
of AGPS and PHYH respectively [136]. However, normal levels of
VLCFA are observed despite of the absence of peroxisomal 3-ketoacyl
Co-A thiolase. This probably is due to the thiolase activity of Sterol
carrier protein X which contains a PTS1 [137].
S. cerevisiae Pex7 mutants are characterized by PTS2 import de-
fects. Motley et al. [138] cloned Kluyveromyces lactis Pex7 by function-
al complementation in S. cerevisiae lacking the endogenous Pex7 and
identiﬁed the conserved residues in Pex7. Multiple sequence align-
ments of the human ORFs with yeast Pex7 led to the identiﬁcation
of the human PTS2 receptor Pex7 and it was conﬁrmed that muta-
tions in human Pex7 are responsible for RCDP1 disorder [135].
Adult Refsum disease is mainly (90% cases) attributed to the per-
oxisomal single enzyme deﬁciency disorder caused by mutations in
phytanoyl-CoA hydroxylase (PHYH). The patients are affected in the
alpha-oxidation pathway [139]. About 10% of the cases of adult
Refsum disease are caused by mutations in Pex7 without any defects
in PHYH [140]. It should be noted that infantile Refsum disease is a
distinct disorder from adult Refsum disease with a different genetic
cause as well as different clinical phenotypes (See Section 3.3).
3.3. Defects in PTS1 and PTS2 protein import
Both PTS1 and PTS2 pathways converge at the peroxisomal mem-
brane where they share the same translocon composed of the docking
peroxins (Pex14, Pex13), RING-ﬁnger peroxins (Pex2, Pex10, Pex12)
and AAA-type ATPase complex peroxins (Pex1, Pex6, Pex26) [102].
Hence a mutation in any one of these components affects the import
of both PTS1 and PTS2 proteins. Mutations in Pex1, Pex2, Pex5L, Pex6,
Pex10, Pex12, Pex13, Pex14, or Pex26 result in general matrix protein
import defects. As a consequence, peroxisomal metabolic pathways
are lost leading to the metabolic abnormalities and form the basis
for the lethal genetic disorders collectively termed ZSS [129].
Cells from ZSS patients suffering from defects in peroxisomal ma-
trix protein import however can still correctly target peroxisomal
membraneproteins andhence they contain remnant peroxisomalmem-
brane structures, called ghosts. In contrast, mutations in the peroxins
Pex3, Pex16 and Pex19 required for the topogenesis of peroxisomal
membrane proteins (PMP) cause mislocalization of PTS1 and PTS2
proteins due to the complete loss of peroxisomes (reviewed by Fujiki
et al. in this issue).ZSS patients exhibit severe congenital neurological abnormalities
like disturbances in neuronal migration and differentiation which
typically leads to death within the ﬁrst year after birth [141]. Hepatic
and renal dysfunctions are also frequently observed and therefore ZSS
is also referred to as cerebrohepatorenal syndrome. Patients with
milder PBDs like NALD or IRD survive relatively longer than ZS patients,
but they also display various progressive developmental defects like
loss of vision and hearing and other symptoms like hypotonia and
seizures. Biochemical features of these PBDs include elevated plasma
levels of very long chain fatty acids (VLCFAs), branched chain fatty
acids, di- and trihydroxycholestanoic acid (DHCA/THCA) and L-pipecolic
acid. On the other hand, deﬁciency of plasmalogens and docosahexanoic
acid (DHA) is observed in the plasma and erythrocytes [142,143].
Peroxisomal disorders were originally described based on clinical
phenotypes without the knowledge of their molecular cause. Several
peroxins involved in peroxisome biogenesis were ﬁrst identiﬁed in
various yeast species or mammalian cells like CHO [15,16]. Using this
knowledge of peroxins from different species, the orthologous human
counterparts were identiﬁed based on their sequence similarity. Subse-
quently, mutations of the hereby identiﬁed human PEX genes were
demonstrated to be responsible for PBDs. Thus, the genetic basis of all
peroxisome biogenesis disorders is known.
Mutational analysis of over 600 cell lines fromPBD patients revealed
that mutations in Pex1 are the most common (58%) followed by Pex6
(16%) [133] with the Gly843Asp substitution being the most common
mutation found in Pex1. This mutation reduces the Pex1–Pex6 interac-
tion [144] and is associated with temperature sensitivity observed in
cell lines that show improved PTS1 import when cells are grown at
30 °C. The repertoire of knowndisease causingmutations in all peroxins
is reported in Ebberink et al. 2011 [133] or is available at www.dbpex.
org.
4. Disorders associated with peroxisomal protein import
4.1. Unique case of acquired peroxisomal targeting
Peroxisomal disorders are associated with genetic defects in per-
oxisome biogenesis genes or single enzyme deﬁciencies. However,
Shepard et al. [145] described a striking link between mutations in a
gene totally unrelated to peroxisomes and a probable role of normal
peroxisomal import in the disease pathology. Mutations in myocilin
(MYOC) gene are the genetic cause of primary open angle glaucoma
(POAG), a disease that belongs to the genetically heterogeneous group
of optic neuropathies. Myocilin is a secreted glycoprotein present in
the trabecular extracellular matrix tissue of the eye and is responsible
for the maintenance of intraocular pressure (IOP) [146,147]. Myocilin
bears a cryptic PTS1 signal at its C-terminus (−SKM). This signal is
not accessible for Pex5 recognition in normal cells since the protein is
secreted via the ER–Golgi pathway [145]. However, mutant myocilin
is retained in the ER leading to ER stress which may trigger ERAD and
dislocate themutant protein to cytosol for degradation via the ubiquitin
proteasome system [148]. The presence of mutant myocilin protein in
the cytosol or the exposure of its cryptic PTS1 due to misfolding, allows
the PTS1 receptor Pex5 to access the PTS1 signal and to target the
mutant myocilin to peroxisomes. The severity and early onset of IOP
elevation is correlatedwith themutations that cause a stronger interac-
tion with Pex5. This indicates that the gain-of-function mutations in
MYOC increases its peroxisomal accumulation, facilitating the progres-
sion of IOP and pathogenesis of POAG [145].
4.2. Exploitation of peroxisomal matrix protein import by pathogens
Several pathogens have been shown to hijack or exploit normal
peroxisome functions at least in part of their life cycle [149]. It has
been described that rotaviruses which cause infantile gastroenteritis,
encode the spike protein VP4 that bears a highly conserved PTS1 signal
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have PTS1 signal variants (SKL, CKL, GKL, CRL, and CRI) of which CRL
is the most common variant (62%).
Rotavirus strain SA11 that encodes VP4 protein with a C-terminal
CRL sequence was used to infect a permissive simian (monkey) cell
line MA104. Peroxisomal localization of VP4 was demonstrated in
virus-infected cells by immunoﬂuorescence microscopy [151].
Transient expression of N-terminally GFP tagged VP4 in COS-7L
cells shows punctate peroxisomal localization while truncation of
C-terminal PTS1 leads to diffuse cytosolic ﬂuorescence. This conﬁrms
that rotaviruses indeed can utilize the normal PTS1 import pathway for
the transport of at least one of its proteins to the host organelle [151].
The functional signiﬁcance or requirement of peroxisomal VP4 for the
virus remains to be elucidated.
Similarly, the presence of functional PTS1 is also found in Poa semi-
latent virus cysteine-richγb protein [152]. Other notable examples of ex-
ploitation of human peroxisomes are association of HIV's Nef protein
with peroxisomal thioesterase and interaction of inﬂuenza virus NS1
protein with peroxisomal 17b-HSD4/MFP-2. However, in both the cases
the physiological relevance of the peroxisome association of these pro-
teins is not known [153,154].
5. Development of therapies and new animal models for PBDs
Early onset of disease and lethality in case of the severe forms
of PBDs has limited scope for the treatment. But patients suffering
from milder forms of PBD and those with longer survival rates have
some scope for correcting or at least slowing down the progressive
developmental defects. Several lines of research are ongoing [155] in-
cluding (a) dietary therapies— limiting the intake of metabolites such
as VLCFA which tend to accumulate due to peroxisomal defects or
supplementing the diet with metabolites like docosahexanoic acid
(DHA), ether lipids and bile acids which are deﬁcient in PBD patients,
(b) stimulating peroxisomal proliferation or peroxisome related gene
expression or (c) screening small molecule compound libraries for new
drugs. Since PBDs are associated with abnormalities in peroxisomal
protein import, recovering or improving import may have beneﬁcial ef-
fects. Here we discuss latest efforts towards the development of such
therapies.
5.1. Nonsense suppressor therapies
Nonsense mutations (point mutation leading to premature stop
codon) are observed in ∼15% of PEX gene alleles in PBD patients.
Dranchak et al., 2011 [156] evaluated whether nonsense suppressor
therapies which promote the translation read-through can be utilized
to restore expression of an active peroxin [156]. Pex2- and Pex12-
defective patient ﬁbroblasts responded well to nonsense suppressor
therapy, which led to an improvement of peroxisomal VLCFA metab-
olism and plasmalogen biosynthesis. Immunoﬂuorescence microscopy
analysis of treated cells showed recovery of peroxisomal assembly.
On the other hand, RCDP1 related Pex7 nonsense mutations did not
respond to PTC124 (ataluren) mediated read-through. Nonetheless,
the positive results observed for the Pex2- and Pex12-defective cells
provide a proof of concept for using nonsense suppressor therapies for
PBDs which certainly needs further attention.
5.2. Small molecule screening for rescuing the peroxisomal import
Peroxin mutations may lead to misfolding or instability of the pro-
tein or reduced interaction with its binding partners. Small molecule
compoundsmay alleviate these defects bymechanisms such as assisting
proper folding. A high-content screening assaywas developed by Zhang
et al., 2010 for screening small molecule compounds which can recover
peroxisomal import functions [157]. The studywasbased on the expres-
sion of GFP–PTS1 reporter in patient ﬁbroblasts carrying the commondisease allele PEX1–Gly843Asp and treatment with a chemical library
of small molecule drugs. Recovery of peroxisomal import indicated by
redistribution of cytosolic GFP–PTS1 reporter to peroxisomes after
drug treatment was assessed by high-content imaging. Upon screening
of 2080 bioactive compounds, four molecules were found to recover
GFP–PTS1 import into peroxisomes. Further validation of peroxisomal
import and metabolism recovery was done by three independent as-
says; import of native peroxisomal proteins, plasmalogen synthesis
and processing of PTS2. This robust and high-throughput screening
protocol opens up new frontiers in exploring novel drug therapy for
PBD treatment.5.3. Stimulating peroxisome proliferation
Sodium 4-phenylbutyrate induces peroxisome proliferation and
improves biochemical function in ﬁbroblast cell lines from patients
with milder PBD phenotypes [155]. Recently, docosahexaenoic acid
(DHA, C22:6n−3) was identiﬁed as an inducer of peroxisome divi-
sion [158]. Treatment of ﬁbroblasts from patients that carry defects
in peroxisomal fatty acid β-oxidation with DHA induced the prolifer-
ation of peroxisomes to the level seen in normal ﬁbroblasts [158].
Earlier studies demonstrated that also patients with milder PBD phe-
notypes could beneﬁt from DHA-treatment [159,160], indicating that
the pharmacological induction of peroxisomes in PBD patients might
be another worth pursuing approach to improve overall peroxisomal
biochemical function.5.4. New model systems for studying PBDs
Our knowledge of peroxisome biogenesis is mostly obtained from
studies on yeast or mammalian cells whichwere instrumental in identi-
fying the corresponding humanperoxins and themolecular basis under-
lying peroxisomal disorders. However, to gain insight into how these
mutations correlate with the pathogenesis of the disease phenotype
and the developmental defects, there is a need for complexmulticellular
animal model systems. Mouse models of PBDs were generated by
targeted deletion of Pex2, Pex5, Pex7 and Pex13 as well as conditional
knockouts of Pex5 and Pex13 which allow tissue-speciﬁc inactivation
of these peroxins [161].
An interesting mouse model concerns PEX11β, a peroxisomal
membrane protein which plays an important role in the peroxisome
proliferation [19,162,163]. Accordingly, in this mouse model, the loss
of PEX11β resulted in a reduction of peroxisome abundance and in-
creased peroxisome clustering and elongation [162]. The Pex11β knock-
out mice exhibited a similar clinical phenotype as observed in human
PBDs. However, no defects in peroxisomal protein import or changes
in the levels of VLCFA or plasmalogens in tissues were observed, thus
challenging the view of involvement of import defects or VLCFA toxicity
in the disease pathogenesis [162].
C. elegans as a model system to probe human PBDs is described in
[164,165]. Knockdown of ﬁve peroxin homologs of Pex5, Pex6, Pex12,
Pex13 and Pex19 by RNA-mediated interference (RNAi) led to a devel-
opmental arrest in early larval stage. A drawback of the C. elegans system
is that the PTS2 pathway does not exist in this organism, hence this
model is not applicable for the study of RCDP1 which displays PTS2 im-
port defects [37].
More recently,Drosophilamodels of PBDs have been described.Mast
et al. [166] utilized cultured Drosophila cells to characterize effects of
RNAi mediated knockdown of fourteen predicted Drosophila PEX gene
homologs. Drosophila larvae harboring inherited PEX1 mutations most
frequently found in PBD patients showed developmental defects analo-
gous to Zellweger syndrome patients. Studies on Drosophila PEX mu-
tants also demonstrated their requirement for germ cell development
and VLCFA metabolism [167,168].
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The combination of data derived from human patient cells as well
as model organisms like yeast merges into a more detailed picture of
the peroxisomal matrix protein import. Even though there are some
species-speciﬁc differences, the basic principles of peroxisomal protein
import are well conserved among species. Nevertheless, an important
question is whether all major components of the human peroxisomal
protein importmachinery have been identiﬁed. This is especially evident
when comparing S. cerevisiae, which utilizes twenty-seven peroxins
from which sixteen are dedicated to matrix protein import, with
humans, where seventeen proteins required for biogenesis have been
described, from which nine are linked to matrix protein import. So far,
the identiﬁcation of human peroxins has been connected to the study
of patient complementation groups. It has been noted earlier that
mutants affected in peroxisome biogenesis that might cause only a
mild phenotype could have been missed. Most interestingly, recent
work demonstrates that some answers might come from unexpected
directions. For instance, the central function of yeast Pex4 in mono-
ubiquitination of Pex5 seems to be transferred in evolution to three
redundant E2 enzymes, UbcH5a, b and c, probably explaining why
there is nomonogenetic defect of these E2-enzymes relatedwith perox-
isomal disease.Moreover, these E2 enzymes are not peroxisome-speciﬁc
but are also involved in other pathways. Similarly, the recent discovery
of AWP1, the Pex6 adaptor that binds monoubiqitinated Pex5, has
been described to be essential for matrix protein import even though
it also has additional functions in other signaling pathways.
Another major leap in the ﬁeld of peroxisome import came recently
by the identiﬁcation of the peroxisomal import pore in S. cerevisiae.
However there are still several open questions regarding themechanis-
tic aspects of this process like — how is the pore assembled, what is
the driving force for the translocation? How is the cargo released?
How is the opening and closure of the pore regulated? The mechanistic
function of the AAA peroxins in the receptor release and how the recep-
tor release relates to import also needs to be unveiled.
Knowledge obtained from various organisms with respect to the
above and manymore important questions can be utilized to get better
insight of various peroxisomal disorders caused by peroxisomal matrix
protein import defects.
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